FDA has approved new indications for Janssen's risperidone (Risperdal®) for treating schizophrenia in adolescents ages 13-17 and for the short-term treatment of manic or mixed episodes of bipolar 1 disorder in children and adolescents ages 10-17.
FDA has approved new indications for Janssen's risperidone (Risperdal®) for treating schizophrenia in adolescents ages 13-17 and for the short-term treatment of manic or mixed episodes of bipolar 1 disorder in children and adolescents ages 10-17.
New FDA Approvals
October 1, 2007